Imperial College London
Alternate

ProfessorAdolfoBronstein

Faculty of Medicine, Department of Brain Sciences

Emeritus Clinical Professor Head of Neuro-otology Unit
 
 
 
//

Contact

 

+44 (0)20 3313 5525a.bronstein

 
 
//

Assistant

 

Miss Lorna Stevenson +44 (0)20 3313 5525

 
//

Location

 

10 L15bLab BlockCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Harcourt:2019:10.1097/MAO.0000000000002108,
author = {Harcourt, JP and Lambert, A and Wong, PY and Patel, M and Agarwal, K and Golding, JF and Bronstein, AM},
doi = {10.1097/MAO.0000000000002108},
journal = {Otology and Neurotology},
pages = {491--496},
title = {Long-term follow-up of intratympanic methylprednisolone versus gentamicin in patients with unilateral Menière's disease},
url = {http://dx.doi.org/10.1097/MAO.0000000000002108},
volume = {40},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - OBJECTIVES: To determine whether long term (>48 months) symptomatic vertigo control is sustained in patients with Menière's disease from a previous comparative trial of intratympanic methylprednisolone versus gentamicin, and if the two treatments remain nonsignificantly different at long-term follow-up. STUDY DESIGN: Mail survey recording vertigo frequency in the previous one and six months, further intratympanic treatment received, and validated symptom questionnaires. SETTING: Outpatient hospital clinic setting. PATIENTS: Adult patients with definite unilateral refractory Menière's disease, who previously received intratympanic treatment in a comparative trial. INTERVENTION: A survey of trial participants who received intratympanic gentamicin (40mg/mL) or methylprednisolone (62.5mg/mL). OUTCOME MEASURES: Primary: number of vertigo attacks in the 6 months prior to receiving this survey compared with the 6 months before the first trial injection. Secondary number of vertigo attacks over the previous 1 month; validated symptom questionnaire scores of tinnitus, dizziness, vertigo, aural fullness, and functional disability. RESULTS: Forty six of the 60 original trial patients (77%) completed the survey, 24 from the gentamicin and 22 from the methylprednisolone group. Average follow-up was 70.8 months (standard deviation 17.0) from the first treatment injection. Vertigo attacks in the 6 months prior to receiving the current survey reduced by 95% compared to baseline in both drug groups (intention-to-treat analysis, both p<0.001). No significant difference between drugs was found for the primary and secondary outcomes. Eight participants (methylprednisolone=5 and gentamicin=3) required further injections for relapse after completing the original trial. CONCLUSION: Intratympanic methylprednisolone treatment provides effective long-lasting relief of vertigo, without the known inner-ear toxicity associated with gentamicin. There are no significan
AU  - Harcourt,JP
AU  - Lambert,A
AU  - Wong,PY
AU  - Patel,M
AU  - Agarwal,K
AU  - Golding,JF
AU  - Bronstein,AM
DO  - 10.1097/MAO.0000000000002108
EP  - 496
PY  - 2019///
SN  - 1531-7129
SP  - 491
TI  - Long-term follow-up of intratympanic methylprednisolone versus gentamicin in patients with unilateral Menière's disease
T2  - Otology and Neurotology
UR  - http://dx.doi.org/10.1097/MAO.0000000000002108
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30870364
UR  - http://hdl.handle.net/10044/1/68217
VL  - 40
ER  -
Download